drugset / Trial / NCT01199224

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

NCT01199224

Phase 1 Completed 27 enrolled AbbVie
RandomizedCrossoverOpen-labelTreatment

Summary

Compare the bioavailability of three veliparib formulations in subjects with solid tumors.

Timeline

Start
2010-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Veliparib Small molecule 40 mg Oral

Indications